Arch Biopartners Inc (V:ARCH) — Market Cap & Net Worth
Market Cap & Net Worth: Arch Biopartners Inc (ARCH)
Arch Biopartners Inc (V:ARCH) has a market capitalization of $23.34 Million (CA$32.27 Million) as of June 4, 2026. Listed on the V stock exchange, this Canada-based company holds position #24574 globally and #950 in its home market, demonstrating a 6.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arch Biopartners Inc's stock price CA$0.48 by its total outstanding shares 67933289 (67.93 Million). Review ARCH liabilities breakdown to assess the company's total debt and financial obligations.
Arch Biopartners Inc Market Cap History: 2015 to 2026
Arch Biopartners Inc's market capitalization history from 2015 to 2026. Data shows growth from $15.73 Million to $23.34 Million (2.51% CAGR).
Arch Biopartners Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arch Biopartners Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
36.66x
Arch Biopartners Inc's market cap is 36.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $47.67 Million | $93.88K | -$2.36 Million | 507.77x | N/A |
| 2020 | $73.22 Million | $67.89K | -$4.63 Million | 1078.59x | N/A |
| 2021 | $169.54 Million | $3.89 Million | -$1.17 Million | 43.62x | N/A |
| 2022 | $138.09 Million | $964.68K | -$1.39 Million | 143.14x | N/A |
| 2023 | $72.73 Million | $1.98 Million | -$3.33 Million | 36.66x | N/A |
Competitor Companies of ARCH by Market Capitalization
Companies near Arch Biopartners Inc in the global market cap rankings as of June 4, 2026.
Key companies related to Arch Biopartners Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #227 globally with a market cap of $108.72 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $63.77 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #581 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #602 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #227 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.72 Billion | $428.34 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.77 Billion | $618.95 |
| #581 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #602 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Arch Biopartners Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Arch Biopartners Inc's market cap moved from $15.73 Million to $ 23.34 Million, with a yearly change of 2.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$23.34 Million | -61.07% |
| 2025 | CA$59.95 Million | -36.79% |
| 2024 | CA$94.84 Million | +30.41% |
| 2023 | CA$72.73 Million | -47.33% |
| 2022 | CA$138.09 Million | -18.55% |
| 2021 | CA$169.54 Million | +131.54% |
| 2020 | CA$73.22 Million | +53.61% |
| 2019 | CA$47.67 Million | -25.95% |
| 2018 | CA$64.38 Million | +184.78% |
| 2017 | CA$22.61 Million | +13.58% |
| 2016 | CA$19.90 Million | +26.56% |
| 2015 | CA$15.73 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 4th, 2026 the market cap of Arch Biopartners Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.34 Million USD |
| MoneyControl | $23.34 Million USD |
| MarketWatch | $23.34 Million USD |
| marketcap.company | $23.34 Million USD |
| Reuters | $23.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more